Assessing Therapeutic Potential of a New Drug ICG-001 in Glioblastoma

Glioblastoma multiforme (GBM) is the most prevalent and malignant form of brain cancer. Currently, standard care for GBM patients consists of surgical resection, radiation treatment, and chemotherapy. Despite these aggressive treatments, median survival time is only 15 months1, primarily due ineffective elimination of cancer cells and rampant tumor recurrence. While multiple promising drug candidates are in clinical trials, therapeutic potentials of some of these drugs have already been found to fail expectation2. Clearly, new therapeutic avenues for GBMs have to be explored.

This pilot project aims to determine whether a novel compound (ICG-001) can target an unique population of tumor cells called cancer stem cells (CSCs), cancer cells with defining stem cell characteristics. CSCs have been shown to be resistant to current therapies and they have the unique ability to initiate a tumor upon transplantation, suggesting that they are responsible for therapy resistance and tumor recurrence. Our preliminary data suggest that ICG-001 is a potent inhibitor of GBM stem cells in culture. We propose to determine its efficacy in a larger number of independent patient derived GBM stem cell lines to test its general applicability, and to assess the efficacy of the drug in live mice carrying human GBM tumors in their brains.

The Maine Cancer Foundation Pilot Grant program is ideal to fund this proof-of-principle research on testing the efficacy of a new drug (ICG-001) that has the potential to eliminate GBM stem cells. A second-generation compound of ICG- 001 is currently in clinical trial for other cancers (colon and leukemias); therefore, the potential for translating our findings to the clinic is very high and imminent. The preliminary data gathered in this study will prepare us for future grant applications (NIH R21 or R01) to translate our findings to the clinic.

Organization: 
The Jackson Laboratory
Researcher: 
Kin-Hoe Chow, PhD
Grant Amount Given: 
$50,000
Year Issued: 
2013
Period: 
Annual
Grant Category: 
Research
Types of Cancer: 
Brain
Molecular
Grant Duration: 
1 Year Pilot Grant

Maine Cancer Foundation Grants to this Organization:

Year Program Amount Category Organization
2014 Are Micro RNAs the Key to Stopping Lung Cancer? $50,000 Research The Jackson Laboratory
2014 Mouse Models for Acute Myeloid Leukemia $169,834 Research The Jackson Laboratory
2014 A Slice of Life: The Search for Variation in Brain Tumors $50,000 Research The Jackson Laboratory
2014 Genetic Testing for Primary Care Providers: Case-based Web Modules $49,220 Education The Jackson Laboratory
2014 A Secondary Syndrome: Acute Myeloid Leukemia $50,000 Research The Jackson Laboratory
2013 Defining Susceptibility To Transformation By Epigenetic Landscape $49,999 Research The Jackson Laboratory
2013 Assessing Therapeutic Potential of a New Drug ICG-001 in Glioblastoma $50,000 Research The Jackson Laboratory
2013 The Maine Triple-Negative Breast Cancer Study $212,601 Research The Jackson Laboratory
2013 Development of Optimized Ex Vivo Organotypic Slice Culture Systems $164,686 Research The Jackson Laboratory
2012 New Models for Lung Cancer Research $199,036 Research The Jackson Laboratory
2012 Online CME Course $27,600 Education The Jackson Laboratory
2012 FoxC2 Function in glioma stem cells and Vasculature $84,000 Research The Jackson Laboratory
2011 Imaging Glicoma Stem Cell Dynamics in Vivo $90,000 Research The Jackson Laboratory
2010 Genetic Chemotherapy: Inducing Leukemia and Lymphoma Cell Self Destruction $67,500 Research The Jackson Laboratory
2010 Notch Signaling in Medulloblastoma Initiation and Cancer Stem Cell Maintenance $90,000 Research The Jackson Laboratory
2010 MicroRNA Expression during Lung Tumor Progression $90,000 Research The Jackson Laboratory
2009 Validating S100A6 as a Novel Marker and Potential Therapeutic Target of Brain Cancer Stem Cells $80,000 Research The Jackson Laboratory
2008 Homologous Recombination Factor XRCC2 in B-Cell Genome Stability and Tumor Supression $79,696 Research The Jackson Laboratory
2008 Development Genomics of Lung Cancer $79,524 Research The Jackson Laboratory
2006 Chromatin Reorganization in Pro-B Cell Lymphoma Nuclei $74,180 Research The Jackson Laboratory
2006 The Role of Src Kinases in Regulation of Stem Cell Survival in CML $75,000 Research The Jackson Laboratory
2005 A Gene Expression Study for the Hormone Independent Growth Transition of Ovarian Cancer Cells in vivo $20,000 Research The Jackson Laboratory
2004 Malignant Ovarian Granulose Cell Teumorigenesis $37,165 Research The Jackson Laboratory
2003 Parent-of-Origin Genetics in a Model of Ovarian Ganulosa Cell Tumorigenesis $35,500 Research The Jackson Laboratory